Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 25, 2018 02:00 ET | Source: Novartis Pharma AG

Novartis poursuit la transformation à l'échelle mondiale de son réseau de fabrication et de ses activités de services, entraînant une réduction planifiée de ses effectifs en Suisse d'ici 2022

L'adaptation poursuivie du réseau mondial de fabrication de Novartis, basée sur la stratégie annoncée précédemment visant à consolider sa présence et à investir dans de nouvelles plateformes de...
September 25, 2018 02:00 ET | Source: Novartis Pharma AG

Novartis plant, bis 2022 im Zuge weltweiter Anpassungen der Produktion und der internen Dienstleistungen Stellen in der Schweiz zu reduzieren

Die weltweite Anpassung des Produktionsnetzes von Novartis kann bis 2022 einen Nettoabbau von rund 1000 Stellen in der Schweiz zur Folge haben. Dies ist Teil der bereits 2015 initiierten...
September 22, 2018 08:41 ET | Source: Novartis Pharma AG

Novartis to file for new Lucentis® (ranibizumab) indication in retinopathy of prematurity (ROP), a rare disease in premature infants that often leads to blindness

In the Phase III RAINBOW study, despite marginally missing statistical significance for the primary endpoint of demonstrating superiority of Lucentis® to laser surgery, Lucentis was shown to be...
September 22, 2018 08:36 ET | Source: Novartis Pharma AG

New analysis of Novartis Phase III brolucizumab (RTH258) data reinforces superior reduction of retinal fluid, a key marker of disease activity in nAMD

Pre-specified analysis provides insight into maintenance treatment effectiveness with like-for-like comparison of brolucizumab versus aflibercept over entire week 36 to 48 treatment period ...
September 21, 2018 07:26 ET | Source: Novartis Pharma AG

Sandoz receives positive CHMP opinion for proposed biosimilar pegfilgrastim

Positive opinion is based on comprehensive data confirming that Sandoz biosimilar pegfilgrastim matches the reference medicine in terms of safety, efficacy and qualitySandoz seeks approval in...
September 21, 2018 07:25 ET | Source: Novartis Pharma AG

Novartis receives positive CHMP opinion for Gilenya® for the treatment of children and adolescents with MS, marking a major medical advance for young MS patients in Europe

Children and adolescents with multiple sclerosis (MS) experience more frequent and often more severe relapses than adults with the disease, hindering their development and ability to take part in...
September 21, 2018 07:24 ET | Source: Novartis Pharma AG

Novartis announces positive CHMP opinion for one-time gene therapy Luxturna® to treat children and adults with rare inherited retinal disease

If approved in expected timeframe, Luxturna* (voretigene neparvovec) will be first and only gene therapy available in EU to treat a rare inherited retinal disease Children and adults living...
September 17, 2018 16:30 ET | Source: Novartis Pharma AG

World's largest Alzheimer's survey reveals most adults believe a cure will be developed in their lifetime

From a sample of over 10,000 adults, 62% are worried that they may develop Alzheimer's disease and 91% believe the solution to tackling diseases lies in medical research[1] 79% are willing to...
September 17, 2018 01:15 ET | Source: Novartis Pharma AG

Launch of Alcon Experience Academy Reinforces Commitment to Training and Education for Eye Care Professionals

Alcon Experience Academy serves as umbrella for industry-leading training and educational resources for all eye care professionals New website houses a robust library of more than 500 videos,...
September 13, 2018 01:15 ET | Source: Novartis Pharma AG

Novartis real-world evidence confirms efficacy and safety benefits of Cosentyx® in daily life for psoriasis patients

Real-world evidence confirms Cosentyx® efficacy and safety consistent with previously reported clinical studies[1]-[4] Novartis presents a large program of real-world evidence at the 27th...